Head and neck cancers are among the most difficult to treat. They can be aggressive and are located near some of the body's ...

Results from the Phase III KEYNOTE-689 trial show that adding perioperative Keytruda (pembrolizumab) to standard-of-care radiotherapy improves event-free survival in patients with resectable, locally ...

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with resectable locally advanced head and neck squamous ...

Keytruda is approved for resectable locally advanced head and neck squamous cell carcinoma with PD-L1 expression, marking a significant advancement in treatment options. The KEYNOTE-689 trial showed a ...

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with resectable locally advanced head and neck ...

Neoadjuvant and adjuvant pembrolizumab added to standard care significantly improves event-free survival in HNSCC.

Merck's Keytruda wins breakthrough head and neck cancer nod around surgery, but with a limitation By Angus Liu Jun 13, 2025 10:50am Merck & Co. Keytruda head and neck cancer PD-1/L1 ...

The U.S. Food and Drug Administration (FDA) on Friday approved Merck & Co Inc.’s MRK Keytruda (pembrolizumab) for adult patients with resectable locally advanced head and neck squamous cell ...

The researchers found that the cancer stayed the same or got smaller in more than half the people with head and neck cancer who had Reolysin and PC chemotherapy. The trial recruited 31 people with ...

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with resectable locally advanced head and neck ...